Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06545747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI

StatusRecruiting
PhasePhase 3
Started2024-08-01
View on ClinicalTrials.gov ↗

Amendment history

2026-04-03
Study Status, Eligibility v2
Eligibility criteria+64 characters
[...] al type of mixed small cell and non-small cell lung cancer. The presence of sensitive EGFR mutations or ALK rearrangements. Major surgery performed within 4 weeks prior to entering the [...]
2025-07-20
Study Status, Study Design, Outcome Measures v1
Primary completion date2027-12-31→2028-07-31
Completion date2027-12-31→2028-07-31
Start date2024-01-01→2024-08-01
Enrollment target304→490
Secondary endpoints5 to 4 entries
progression-free survival rate
Primary endpoints1 to 2 entries
progression-free survival rate
2024-08-08
Original filing
This study is a randomized phase III trial that aiming to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) guided hypofractionated radiotherapy (hypo-RT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who are planned to receive hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. Patients will be randomized in a 1:1 ratio into two groups: 1. The study group will undergo adaptive dose-painting hypo-RT based on DCE-MRI. 2. The control group will undergo hypo-RT based on enhanced CT. The treatment-related toxicity, local control and long-term survival will be evaluated compared between MRI-guided and CT-guided hypo-RT.
Trial Details
NCT Number NCT06545747
Lead Sponsor Sun Yat-sen University
Conditions Non-small Cell Lung Cancer
Enrollment 490 participants
Start Date 2024-08-01
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-06